• What best describes your title?*
  • How many patients do you currently see each month with GERD?
  • 1. By what primary mechanism does vonoprazan differ from proton pump inhibitors (PPIs) in its acid-suppressive effect, and which GERD patient phenotype is most likely to derive particular benefit from this distinction?*
  • 2. A 52-year-old man with Los Angeles Grade C erosive esophagitis has persistent symptoms and incomplete mucosal healing after an adequate trial of twice-daily PPI therapy. Based on phase 3 data and comparative evidence, which management strategy best aligns with an evidence-based, vonoprazan-inclusive GERD algorithm?*
  • 3. A gastroenterologist initiates vonoprazan for a patient with PPI-refractory GERD and severe erosive esophagitis. Which approach best supports continuity of care and minimizes the risk that a primary care clinician will inadvertently switch the patient back to a PPI?*
  • Learning Objectives
    Rows
  • Please provide us with feedback regarding your experience at the activity:
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: